



17 September 2014

Company Announcements Office
Australian Securities Exchange

New European study shows trophon® EPR high level disinfection for ultrasound probes significantly more effective than manual wipe disinfection

A new study shows trophon EPR high level disinfection for intracavity ultrasound probes is significantly more effective than the manual wipe disinfection procedure which is currently standard in most European countries. When compared directly to trophon EPR's automated process, the manual method demonstrated a threefold higher risk of cross contamination, which means increased risk of infection for patients.

The study, which was carried out by the University Hospital Münster in Germany, was presented at the World Congress of the International Society of Ultrasound in Gynecology and Obstetrics (ISUOG) in Barcelona this week.

"Thanks to trophon EPR we can now offer our patients maximal infection protection during our ultrasound examinations," said Dr Ralf Schmitz, Head of the Department of Prenatal Medicine at the hospital.

The study also highlighted the increased cross contamination risk when ultrasound probe handles are not disinfected with 83% of probe handles showing signs of contamination. Disinfection using trophon EPR's automated process effectively disinfected the handle as well as the body of the probe.

"Effective reprocessing of ultrasound probes is essential for proper infection control," said Michael Kavanagh, CEO and President, Nanosonics. "This European study further confirms the superior efficacy of the automated, validated disinfection delivered by trophon EPR over current conventional manual practice. Despite the manual process being performed under strict study conditions, a threefold higher risk of cross contamination was identified."

The University Hospital Münster is one of the largest university hospitals and highly regarded as a centre of excellence for its leading-edge research programs.

Michael Kavanagh
President / Chief Executive Officer

For more information please contact:

Michael Kavanagh, President/CEO or McGregor Grant, CFO on 02 8063 1600

Kyahn Williamson, Investor Relations, Buchan Consulting on (03) 9866 4722 / kwilliamson@buchanwe.com.au

Ben Oliver, Media Relations, Buchan Consulting on (03) 9866 4722 / boliver@buchanwe.com.au

About Nanosonics

Nanosonics Limited is developing a portfolio of decontamination products designed to reduce the spread of infection. The Company owns intellectual property relating to a unique disinfection and sterilisation technology which can be suited to a variety of markets. Initial market applications are designed for the reprocessing of reusable medical instruments. The Company's first product is designed to disinfect Ultrasound Transducers. In parallel with the commercialisation of this product, Nanosonics is also developing other medical applications and exploring opportunities for its proprietary technology in other industries. For more information about Nanosonics please visit www.nanosonics.com.au